Erratum: Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699)

Tomas Vaisar; Blythe Durbin-Johnson; Kathryn Whitlock; Ilona Babenko; Rajnish Mehrotra; David M. Rocke; Maryam Afkarian

doi:10.2337/dc19-er06a

Erratum: Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699)

Tomas Vaisar, Blythe Durbin-Johnson, Kathryn Whitlock, Ilona Babenko, Rajnish Mehrotra, David M. Rocke, Maryam Afkarian

Research output: Contribution to journal › Comment/debate

Abstract

In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.

Original language	English (US)
Number of pages	1
Journal	Diabetes Care
Volume	42
Issue number	6
DOIs	https://doi.org/10.2337/dc19-er06a
State	Published - Nov 1 2018

Fingerprint

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Cite this

Vaisar, T., Durbin-Johnson, B., Whitlock, K., Babenko, I., Mehrotra, R., Rocke, D. M., & Afkarian, M. (2018). Erratum: Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699). Diabetes Care, 42(6). https://doi.org/10.2337/dc19-er06a

Erratum : Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699). / Vaisar, Tomas; Durbin-Johnson, Blythe; Whitlock, Kathryn; Babenko, Ilona; Mehrotra, Rajnish; Rocke, David M.; Afkarian, Maryam.

In: Diabetes Care, Vol. 42, No. 6, 01.11.2018.

Research output: Contribution to journal › Comment/debate

@article{9aaa399f92a24cabb262fd6496692414,

title = "Erratum: Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699)",

abstract = "In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.",

author = "Tomas Vaisar and Blythe Durbin-Johnson and Kathryn Whitlock and Ilona Babenko and Rajnish Mehrotra and Rocke, {David M.} and Maryam Afkarian",

year = "2018",

month = nov,

day = "1",

doi = "10.2337/dc19-er06a",

language = "English (US)",

volume = "42",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "6",

}

TY - JOUR

T1 - Erratum

T2 - Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699)

AU - Vaisar, Tomas

AU - Durbin-Johnson, Blythe

AU - Whitlock, Kathryn

AU - Babenko, Ilona

AU - Mehrotra, Rajnish

AU - Rocke, David M.

AU - Afkarian, Maryam

PY - 2018/11/1

Y1 - 2018/11/1

N2 - In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.

AB - In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.

UR - http://www.scopus.com/inward/record.url?scp=85066456138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066456138&partnerID=8YFLogxK

U2 - 10.2337/dc19-er06a

DO - 10.2337/dc19-er06a

M3 - Comment/debate

C2 - 30936112

AN - SCOPUS:85066456138

VL - 42

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -

Access to Document

10.2337/dc19-er06a